Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report

Oncology · ChemotherapiesExample report

Mercaptopurine

Purinethol

Use as directed

Both genes that affect this drug look normal, so a standard starting dose is expected.

The genes behind this label

The guidelines read 2 genes for mercaptopurine. Each card shows the two copies this person inherited and what they mean.

TPMT*1/*1

Normal metabolizer

Both copies work normally.

Breaks down thiopurines such as azathioprine and mercaptopurine.

This result doesn't change the label.

Normal metabolizer

Both copies work normally.

Breaks down the active form of thiopurines such as azathioprine.

This result doesn't change the label.

What each guideline says about your result.

TPMTNormal metabolizerNUDT15Normal metabolizer

CPIC guideline, both genes together

In plain words: Both genes that affect this drug look normal, so a standard starting dose is expected.
What it means: Both TPMT and NUDT15 predict normal thiopurine metabolism and a normal risk of myelosuppression.
What the guideline suggests: Initiate therapy with standard starting dose of mecaptopurine (e.g., 75 mg/m2/day for malignancy or 1.5 mg/kg/day for nonmalignancy). During therapy, adjust the doses of myelosuppressive agents, as per standard clinical practice. It usually takes at least 2 weeks of stable dosing to reach steady state after each dose adjustment.

From the combined TPMT and NUDT15 table in CPIC's thiopurine guideline.

CPIC reads your TPMT and NUDT15 results together for mercaptopurine, so this label reflects both genes.

Mercaptopurine (6-MP) is a thiopurine taken by mouth.

Used for: Acute lymphoblastic leukemia, as part of combination maintenance chemotherapy (the FDA-approved use); also used outside its label for inflammatory bowel disease and other immune conditions

Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.